MedTrace Logo

Trial to Evaluate the Efficacy and Safety of Tarceva and Capecitabine in Advanced Pancreatic Cancer Patients

NCT00873353 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2010-08-18

No results posted yet for this study

Summary

The purpose of this study is to determine efficacy of the treatment with erlotinib in combination with capecitabine in patients with advanced pancreatic cancer.

Conditions

  • Metastatic Adenocarcinoma of the Pancreas

Interventions

DRUG

capecitabine + erlotinib

6 cycles (3 weeks each one) of : * capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks * erlotinib (Tarceva®) 150mg/day, oral. Days: every days

Sponsors & Collaborators

  • Grupo Gallego de Investigaciones Oncologicas

    lead OTHER

Principal Investigators

  • Rafel López López, Coordinator · Grupo Gallego de Investigaciones Oncológicas

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2008-08-31
Completion
2010-08-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00873353 on ClinicalTrials.gov